Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-Up of EBT-101 in HIV-1
NCT05143307Phase 1Enrolling by invitation
- Sponsor
- Excision BioTherapeutics
- Start
- Jul 2023
- Primary completion
- Jan 2037
- Modality
- Gene Silencing, CRISPR-Cas9, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EBT-101 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Excision BioTherapeutics. Primary endpoint: Long-term safety of EBT-101 at 15 years. Started Jul 2023; status: enrolling by invitation.
02
Drugs
EBT-101
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05143307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143307.